EXTRAINTESTINAL MANIFESTATIONS OF INFLAMMATORY BOWEL DISEASES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the review of modern concepts regarding the diagnosis and therapy of extraintestinal manifestations in ulcerative colitis and Crohn's disease. The insufficient knowledge of the genesis of extraintestinal manifestations in these diseases is noted, the leading role of the complex of genetic factors, immune response and environmental factors is emphasized. It is concluded that treatment of extraintestinal manifestations should be carried out taking into account the course of the IBD and the multidisciplinary approach, which requires close cooperation of doctors of various specialties.

Full Text

Restricted Access

About the authors

Anna V. KAGRAMANOVA

PhD, senior researcher of the Department of inflammatory bowel diseases, Moscow Clinical Scientific Practical Center. 111123, Moscow, 86 Entuziastov sh

Svetlana F. MIKHAILOVA

MD, leading researcher, Moscow Clinical Scientific Practical Center. 111123, Moscow, 86 Entuziastov sh

Oleg V. KNYAZEV

MD, head of the Department of inflammatory bowel diseases, Moscow clinical scientific practical center 111123, Moscow, 86 Entuziastov sh

Nina A. FADEEVA

PhD, senior researcher of the Department of inflammatory bowel diseases, Moscow Clinical Scientific Practical Center 111123, Moscow, 86 Entuziastov sh

Al’bina A. LISHCHINSKAYA

PhD, researcher of the Department of inflammatory bowel diseases, Moscow Clinical Scientific Practical Center. 111123, Moscow, 86 Entuziastov sh

Askold I. PARFENOV

MD, professor, Moscow Clinical Scientific Practical Center. 111123, Moscow, 86 Entuziastov sh

References

  1. De Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullet J.B., Massart S., Collini S., Pieraccini G., Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. USA. 2010;107:14691-6.
  2. Bager P., Simonsen J., Nielsen N.M., Frisch M. Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm. Bowel Dis. 2012.
  3. Hviid A., Svanström H., Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60:49-54.
  4. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-24.
  5. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., Lees C.W., Balschun T., Lee J., Roberts R., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 2010;42:11 18-25.
  6. Vavricka S.R., Rogler G., Gantenbein C., Spoerri M., Prinz Vavricka M., Navarini A.A., French L.E., Safroneeva E., Four nier N., Straumann A., Froehlich F., Fried M., Michetti P., Seibold F., Lakatos P.L., Peyrin-Biroulet L., Schoepfer A.M. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm. Bowel Dis. 2015;21(8):1794-80.
  7. Mendoza J.L., Lana R., Taxonera C., et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med. Clin. (Barc). 2005;125:297-300.
  8. Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 2001;96:1 116-22.
  9. Geng X., Biancone L., Dai H.H., Lin J.J., Yoshizaki N., Dasgupta A., Pallone F., Das K.M. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912-22.
  10. Biancone L., Mandal A., Yang H., Dasgupta T., Paoluzi A.O., Marcheggiano A., Paoluzi P., Pallone F., Das K.M. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology. 1995;109:3-12.
  11. Su C.G., Judge T.A., Lichtenstein G.R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Clin. North Am. 2002;31:307-27.
  12. Van Sommeren S., Janse M., Karjalainen J., Fehrmann R., Franke L., Fu J., Weersma R.K. Extraintestinal manifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways. Inflamm. Bowel Dis. 2014;20(6):987-94.
  13. Roussomoustakaki M., Satsangi J., Welsh K., Louis E., Fanning G., Targan S., Landers C., Jewell D.P. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997;1 12:1845-53.
  14. Orchard T.R., Chua C.N., Ahmad T., Cheng H., Welsh K.I., Jewell D.P. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123:714-8.
  15. Ott C., Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat. Rev. Gastroenterol. Hepatol. 2013;10:585-95.
  16. Парфенов А.И. Энтерология: руководство для врачей. 2-е изд., перераб. и доп. М.: Медицинское информационное агентство, 2009. 880 с. [Parfenov A.I. Enterology: Guide for physicians. 2nd ed. Moscow: Medical information Agency, 2009. 880 p. (in Russ.)]
  17. Aydin S.Z., Maksymowych W.P., Bennett A.N., et al. Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. Annals of the rheumatic diseases. 2012;71:56-60.
  18. Steer S., Jones H., Hibbert J., Kondeatis E., Vaughan R., Sanderson J., Gibson T. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J. Rheumatol. 2003;30:518-22.
  19. Orchard T.R., Holt H., Bradbury L., Hammersma J., McNally E., Jewell D.P., Wordsworth B.P. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn's disease. Alimentary pharmacology & therapeutics. 2009;29:193-7.
  20. Poddubnyy D., Rudwaleit M., Haibel H., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Annals of the rheumatic diseases. 2011;70:1369-74.
  21. Brown M.A., Pile K.D., Kennedy L.G., Calin A., Darke C., Bell J., Wordsworth B.P., Cornélis F. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Annals of the rheumatic diseases. 1996;55:268-70.
  22. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-24.
  23. Reveille J.D. Genetics of spondyloarthritis -- beyond the MHC. Nature reviews. Rheumatology. 2012;8:296-304.
  24. Chen J., Lin S., Liu C. Sulfasalazine for ankylosing spondylitis. The Cochrane database of systematic reviews. 2014;11:CD004800.
  25. Fagerli K.M., van der Heijde D., Heiberg M.S., et al. Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study. Rheumatology (Oxford, England). 2014;53:1087-94.
  26. Bakker S.F., Dik V.K., Witte B.I., Lips P., Roos J.C., Van Bodegraven A.A. Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation. Journal of Crohn's & colitis. 2013;7:377-84.
  27. Timani S., Mutasim D.F. Skin manifestations of inflammatory bowel disease. Clin. Dermatol. 2008;26:265-73.
  28. Huang W., McNeely M.C. Neutrophilic tissue reactions. Adv. Dermatol. 1997;13:33-64.
  29. Callen J.P., Jackson J.M. Pyoderma gangrenosum: an update. Rheum. Dis. Clin. North Am. 2007;33:787-802.
  30. Carinanos I., Acosta M.B., Domenech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm. Bowel Dis. 2011;17:E153-4.
  31. Poritz L.S., Lebo M.A., Bobb A.D., Ardell C.M., Koltun W.A. Management of peristomal pyoderma gangrenosum. J. Am. Coll. Surg. 2008;206:31 1-5.
  32. Cohen P.R. Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet. J. Rare Dis. 2007;2:34.
  33. Marzano A.V., Ishak R.S., Saibeni S., Crosti C., Meroni P.L., Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin. Rev. Allergy Immunol. 2013;45:202-10.
  34. Martin T.M., Smith J.R., Rosenbaum J.T. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr. Opin. Rheumatol. 2002;14:337-41.
  35. Thackeray E.W., Charatcharoenwitthaya P., Elfaki D., Sinakos., Lindor K.D. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin. Gastroenterol. Hepatol. 2011;9:52-6.
  36. Ghabril M., Bonkovsky H.L., Kum C., Davern T., Hayashi P.H., Kleiner D.E., Serrano J., Rochon J., Fontana R.J., Bonacini M. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin. Gastroenterol. Hepatol. 2013;11:558-64.
  37. Landman C., Nahon S., Cosnes J., Bouhnik Y., Brixi-Benmansour H., Bouguen G., Colombel J.F., Savoye G., Coffin B., A bitbol V., Filippi J., Laharie D., Moreau J., Veyrac M., Allez M., Marteau P. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2013;19:582-9.
  38. Pukitis A., Zake T., Groma V., Ostrovskis E., Skuja S., Pokrotnieks J. Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: case report and review of the literature. J. Gastrointestin. Liver Dis. 2013;22:333-6.
  39. Tofteland N.D., Nassif I.I. Abnormal liver enzymes in a patient with Crohn's disease, psoriatic arthritis, and recurrent pancreatitis. Answer to the clinical challenges and images in GI question: image 5: Idiopathic granulomatous hepatitis. Gastroenterology. 2010;139:e14-5.
  40. Ledder O., Lemberg D.A., Day A.S. Thiopurine-induced pancreatitis in inflammatory bowel diseases. Expert Rev. Gastroenterol. Hepatol. 2015;9(4):399-403.
  41. Deepak P., Stobaugh D.J., Sherid M., Sifuentes H., Ehrenpreis E.D. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol. Ther. 2013;38:388-96.
  42. Solomon A.J., Spain R.I., Kruer M.C., Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult. Scler. 2011;17:1472-87.
  43. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 2012;71:1524-9.
  44. Kristensen S.L., Ahlehoff O., Lindhardsen J., et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death - a Danish nationwide cohort study. PLoS One. 2013;8:e56944.
  45. Bewtra M., Kaiser L.M., TenHave T., Lewis J.D. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm. Bowel Dis. 2013;19:599-613.
  46. Jussila A., Virta L.J., Pukkala E., Färkkilä M.A. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J. Crohns Colitis. 2014;8:1088-96.
  47. Oussalah A., Gueant J.L., Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol. Ther. 2011;34:1173-84.
  48. Tan V.P., Chung A., Yan B.P., Gibson P.R. Venous and arterial disease in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2013;28:1095-1 13.
  49. Keely S., Talley N.J., Hansbro P.M. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012;5:7-18.
  50. Михайлова З.Ф., Парфенов А.И., Ручкина И.Н., Рогозина В.А. Состояние функции внешнего дыхания у больных с болезнью Крона. Экспериментальная и клиническая гастроэнтерология. 2011;2:82-3. [Mikhailova Z.F., Parfenov A.I., Ruchkina I.N., Rogozina V.A. The state of the external respiration function in patients with Crohn's disease. Experimental and clinical gastroenterology. 2011;2:82-3 (in Russ.)]
  51. Kim J.H., Lee J.H., Koh E.S., Park S.W., Jang A.S., Kim D., Park C.S. Acute eosinophilic pneumonia related to a mesalazine suppository. Asia Pac. Allergy. 2013;3(2):136-9.
  52. Fiorino G., Danese S., Pariente B., Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun. Rev. 2014;13:15-9.
  53. Gisbert J.P., Gonzalez-Lama Y., Mate J. 5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 2007;13:629-38.
  54. Bennett W.M. Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Ren. Fail. 1996;18:453-60.
  55. Koutroumpakis E.I., Tsiolakidou G., Koutroubakis I.E. Risk of venous thromboembolism in patients with inflammatory bowel disease. Semin. Thromb Hemost. 2013;39:461-8.
  56. Lotaibi G., Alsaleh K., Wu C., McMurtry M.S. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Int. Angiol. 2014;33:301-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies